c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells

[1]  O. Olopade,et al.  CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors , 2010, Breast Cancer Research and Treatment.

[2]  K. Gardner,et al.  Transcriptional autoregulation by BRCA1. , 2010, Cancer research.

[3]  Junjie Chen,et al.  PALB2 Regulates Recombinational Repair through Chromatin Association and Oligomerization* , 2009, The Journal of Biological Chemistry.

[4]  Peter A. Jones,et al.  Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. , 2007, Cancer cell.

[5]  M. L. Beau,et al.  Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins , 2007, Oncogene.

[6]  T. Schlange,et al.  Novel c‐MYC target genes mediate differential effects on cell proliferation and migration , 2007, EMBO reports.

[7]  P. Glazer,et al.  Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites , 2006, Cancer biology & therapy.

[8]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[9]  M. Loda,et al.  c-Myc phosphorylation is required for cellular response to oxidative stress. , 2006, Molecular cell.

[10]  M. Q. Kemp,et al.  The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. , 2006, Cancer research.

[11]  Eivind Hovig,et al.  Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling , 2006, Nucleic acids research.

[12]  R. Bristow,et al.  Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. , 2005, Cancer research.

[13]  O. Olopade,et al.  BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. , 2005, Cancer research.

[14]  Weili Ma,et al.  p53-Dependent Transcriptional Repression of c-myc Is Required for G1 Cell Cycle Arrest , 2005, Molecular and Cellular Biology.

[15]  B. Jeffy,et al.  An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. , 2005, Neoplasia.

[16]  Melissa A. Brown,et al.  Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene. , 2005, Genomics.

[17]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[18]  T. Rauch,et al.  53BP1 is a Positive Regulator of the BRCA1 Promoter , 2005, Cell cycle.

[19]  R. Gaynor,et al.  Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. , 2005, Molecular cell.

[20]  T. Kouzarides,et al.  Myc represses transcription through recruitment of DNA methyltransferase corepressor , 2005, The EMBO journal.

[21]  S. McMahon,et al.  Analysis of genomic targets reveals complex functions of MYC , 2004, Nature Reviews Cancer.

[22]  L. Huang,et al.  HIF‐1α induces cell cycle arrest by functionally counteracting Myc , 2004 .

[23]  C. Perou,et al.  MYC Is Amplified in BRCA1-Associated Breast Cancers , 2004, Clinical Cancer Research.

[24]  W. Du,et al.  Critical role of active repression by E2F and Rb proteins in endoreplication during Drosophila development , 2003, The EMBO journal.

[25]  E. Rosen,et al.  BRCA1 gene in breast cancer , 2003, Journal of cellular physiology.

[26]  C. Croce,et al.  Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors , 2003, Molecular and Cellular Biology.

[27]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[28]  S. Safe,et al.  Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. , 2002, Molecular endocrinology.

[29]  A. Menssen,et al.  Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  E. Atlas,et al.  A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element , 2001, Oncogene.

[32]  C B Begg,et al.  The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  M. Esteller.  Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. , 2000, European journal of cancer.

[34]  E. Atlas,et al.  GA-binding protein α/β is a critical regulator of the BRCA1 promoter , 2000, Oncogene.

[35]  D. Easton,et al.  Risk models for familial ovarian and breast cancer , 2000, Genetic epidemiology.

[36]  D. Livingston,et al.  Genetic analysis of BRCA1 function in a defined tumor cell line. , 1999, Molecular cell.

[37]  P. Goss,et al.  Transcription of BRCA1 Is Dependent on the Formation of a Specific Protein-DNA Complex on the Minimal BRCA1 Bi-directional Promoter* , 1999, The Journal of Biological Chemistry.

[38]  C. Croce,et al.  Positive Regulation of the BRCA1 Promoter* , 1999, The Journal of Biological Chemistry.

[39]  F. O'Malley,et al.  CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site , 1998, Oncogene.

[40]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[41]  E. Solomon,et al.  Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 gene. , 1997, Human molecular genetics.

[42]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[43]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[44]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[45]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[46]  B. Amati,et al.  Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. , 1993, Nucleic acids research.

[47]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  R. Shiu,et al.  Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. , 1987, Cancer research.

[49]  K. Gardner,et al.  Transcriptional Autoregulation by BRCA 1 , 2010 .

[50]  D. Butcher,et al.  Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. , 2007, European journal of cancer.

[51]  M. Jasin,et al.  Measuring recombination proficiency in mouse embryonic stem cells. , 2005, Methods in molecular biology.

[52]  J. Barrett,et al.  HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. , 2004, The EMBO journal.

[53]  S. Angeloni,et al.  Regulation of estrogen receptor- expression by the tumor suppressor gene p53 in MCF-7 cells , 2004 .

[54]  E. Atlas,et al.  GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter. , 2000, Oncogene.